Views & Analysis

As part of pharmaphorum’s Eye on Innovation series, Richard Staines spoke to John Zibert, chief medical officer at

The happiness factor

https://pharmaphorum.com/r-d/views-analysis-r-d/happiness-factor-dermatological-conditions/

R&D/ Views & Analysis/ Views and analysis

R&D roundup: the ups and downs of CRISPR and Alzheimer’s

George Underwood Alzheimer's, CRISPR, R&D, Roche, Vertex Pharma 0 Comment

While the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm

R&D roundup: the ups and downs of CRISPR and Alzheimer’s

https://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-the-ups-and-downs-of-crispr-and-alzheimers/

Brexit/ R&D/ Views & Analysis/ Views and analysis

What will a no-deal Brexit mean for pharma and healthcare?

George Underwood Brexit, NHS, research 0 Comment

Britons are bracing themselves for the UK’s imminent departure from the European Union. A worst-case scenario would see

What will a no-deal Brexit mean for pharma and healthcare?

https://pharmaphorum.com/views-and-analysis/what-will-a-no-deal-brexit-mean-for-pharma-and-healthcare/

R&D/ Views & Analysis/ Views and analysis

Inspiring a new generation of women in pharma

Richard Staines Merck, MSD, women in science 0 Comment

As part of a series of articles highlighting the role of women in the pharma industry, Richard Staines

Inspiring a new generation of women in pharma

https://pharmaphorum.com/views-and-analysis/inspiring-a-new-generation-of-women-in-pharma/

R&D/ Views & Analysis/ Views and analysis

Taking plasma from donor to patient

George Underwood CSL Behring, plasma 0 Comment

Lutz Bonacker from CSL Behring tells us about the unique aspects of working with plasma-derived medicines and how

Taking plasma from donor to patient

https://pharmaphorum.com/views-and-analysis/taking-plasma-from-donor-to-patient/

Evidera machine learning pharmaceutical development

R&D/ Views & Analysis/ Views and analysis

Opening doors in pharmaceutical development

Dominic Tyer AI, Deep Dive: Disruptive Technologies, Evidera, machine learning, research 0 Comment

Evidera surveys the adoption of machine learning by the pharmaceutical industry and looks at how it can increase

Opening doors in pharmaceutical development

https://pharmaphorum.com/r-d/evidera-machine-learning-pharmaceutical-development/

R&D/ Views & Analysis/ Views and analysis

Women in Science: AstraZeneca

George Underwood AstraZeneca, Executive insights, women in science 0 Comment

We speak to three of AstraZeneca’s senior leaders about their careers, the future of their therapy areas and

Women in Science: AstraZeneca

https://pharmaphorum.com/r-d/views-analysis-r-d/women-in-science-astrazeneca/

generics Paul Tredwell Eye on Innovation

R&D/ Views & Analysis/ Views and analysis

Adding value to generics and biosimilars

Richard Staines eye on innovation, Paul Tredwell 0 Comment

Paul Tredwell, vice president for specialty brands at Accord Healthcare says innovation is vital for success in today’s

Adding value to generics and biosimilars

https://pharmaphorum.com/r-d/views-analysis-r-d/adding-value-to-generics-and-biosimilars/

R&D/ Views & Analysis/ Views and analysis

R&D roundup – Sage impresses at JP Morgan

George Underwood AbbVie, Biogen, J&J, JP Morgan, Sage Therapeutics 0 Comment

One of the biggest headline-grabbers at the 2019 JP Morgan Healthcare conference this week was Sage Therapeutics unveiling

R&D roundup – Sage impresses at JP Morgan

https://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-sage-impresses-at-jp-morgan/

«‹ 40 41 42 43 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

Views & Analysis

Login